Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.
The US Food and Drug Administration will not require all employees to resume their daily treks to the office going forward, choosing a “hybrid workplace model” that will go into effect in January 2023.
Commissioner Robert Califf made the change after the agency completed a six-month pilot exploring workplace flexibilities. The FDA said the...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
